Abstract. Apsari PP, Budiarti S, Wahyudi AT. 2019. Actinomycetes of rhizosphere soil producing antibacterial compounds against Urinary Tract Infection bacteria. Biodiversitas 20: 1259-1265. Based on the ability of actinomycetes as an antibacterial compounds producer and the need of finding novel antibacterial compounds, this study aims to look for antibacterial compounds from rhizosphere actinomycetes against bacteria in urine of UTI patients (Escherichia coli, Citrobacter braakii, Acinetobacter calcoaceticus, and Klebsiella pneumoniae). The screening of 21 actinomycetes was conducted based on the paper disc method. Potential actinomycetes that inhibited test bacteria were, then cultured in liquid medium and the supernatant was tested to six test bacteria. Then, the supernatant was extracted using ethyl acetate and crude extract from extraction process was tested to test bacteria. Afterward, the crude extract was scanned for bioactive compounds by GC-MS. Potential actinomycetes were identified by 16S rRNA gene to reveal the species. The screening results showed that ARJ 16, 24, and 36 had a wider inhibition zone than others. All of them showed that the supernatant and the crude extract could inhibit UTI's bacteria. The highest abundance of bioactive compound of crude extract was found in Propane, 1,2-dichloro, n-Hexadecanoic acid, and Carbonochloridic acid, 2-chloroethyl ester, respectively. Identification of potential actinomycetes based on 16S rRNA gene showed that ARJ 16 and ARJ 24 were highly similar to Streptomyces sp. in 99% and ARJ 36 was similar to Streptomyces tendae in 98%.
INTRODUCTION
The number of Multi-Drug Resistance (MDR) cases all over the world are still high and increasing each year (WHO 2018) . There are some reports regarding MDR evidence, indicating that the rate of bacteria experienced MDR to cephalosporin significantly increased from 9.6% to 12% between 2011 and 2014 in Europe (ECDC 2015) . In Southeast Asia, the resistance rate of bacteria to carbapenem (64.91%) and multidrug (58.51%) showed high percentage (Teerawattanapong et al. 2018) . On the other hand, most E. coli (64.9%) from UTI patients in Nepal was reported to have resistance against antibiotics (Parajuli et al. 2017) . Klebsiella pneumoniae also showed significant resistance to several antibiotic classes by multi mechanisms in worldwide (Navon-Venezia et al. 2017) . Acinetobacter is one of nosocomial bacteria in America Latin, resistant to carbapenem class antibiotic in high prevalence (Gonzalez-Villoria and Valverde-Garduno 2016) . The reports above showed that most countries have bacteria resistance diversity to some antibiotics. The bacteria resistance probably results in difficulties and expensive treatments. MDR bacteria which cannot be handled properly perhaps will cause a high mortality and morbidity rate. One of the solutions that can be offered is to search and to find novel antibacterial compounds. Unfortunately, at the moment, the findings related to novel antibacterial compounds are still rare. New discoveries of antibacterial drugs have been slowing since over decades ago (Projan and Shlaes 2016) . Due to the risk and novel antibacterial necessity, research on antibacterial compound from our environment is therefore needed.
Some bacteria can be used as a source of antibacterial compounds, which are Actinomycetes. Actinomycetes can be found in soil, but mostly in plant decomposition areas (Wang et al. 2016) . The majority (66%) of rhizosphere actinomycetes were Streptomyces genera. This bacteria group has high guanine and cytocin contents (more than 51%) in their DNA which support a good metabolism for producing several bioactive compounds (Ventura et al. 2007) . They are special microorganisms because of their ability to produce antibacterial compound in variance and abundance. That was evidenced by the discovery of 160 antibiotics for human therapy; 140 of them produced by actinomycetes (Berdy 2005) . The inhibition effectivity of actinomycetes inhibiting marine, Antartic, and plant endophyte were different. Actinomycetes isolated from Antartic soil produce antimicrobial compounds against Candida albicans, Staphylococcus aureus, and Pseudomonas aeruginosa (Lee et al. 2012) . Marine actinomycetes Streptomyces atratus SCSIO ZH16Ma produce L-3-nitrotyrosine and L-2-amino-4-hexenoic acid as antimycobacterial in tuberculosis patient (Ma et al. 2017 (Silva-Lacerda et al. 2016) . Based on the different ability in some locations, the inhibition effectivity of rhizosphere actinomycetes was suspected of being different. In addition, although they were isolated from the same soil sample, the characters of bioactive compounds from the condition of the areas are different. The quality of bioactive compound produced by dry soil actinomycetes is better than that produced in wet area such as: more stable, good soluble, and bioavailable (Mohammadipanah and Wink 2016) . It means that this bacteria group is still potential to be used as a source of novel antibacterial compound for some infectious diseases. Christine et al. (2018) reported that Escherichia coli, Acinetobacter calcoaceticus, Citrobacter braakii, and Klebsiella pneumoniae were found in UTI urine patients. In accordance with the requirement of new antibacterial compounds and the existence of actinomycetes in rhizosphere, this research conducted some methods to find novel antibacterial compounds from actinomycetes for bacteria from UTI patients as a target.
MATERIALS AND METHODS

Enrichment of actinomycetes and UTI's bacteria
This study started with the enrichment of two bacteria groups used in this study. The first group consisted of 21 actinomycetes from maize of rhizosphere soil in Nusa Tenggara Timur, Indonesia that was collected in Laboratory of Microbiology, IPB and routinely cultured on International Streptomyces Project (ISP) 4 (inorganic saltsstarch agar) medium. Another group included was six UTI's bacteria , Acinetobacter calcoaceticus, Citrobacter braakii, and Klebsiella pneumoniae) routinely cultured on Eosin Methylene Blue Agar (EMBA) and Nutrient Agar (NA) medium. Actinomycetes were cultured at room temperature (27-30 o C) for 7-14 days, while UTI's bacteria were cultured at 37 o C for 24-48 hours.
Afterward, the screening step was conducted based on Kirby Bauer method (Bauer et al. 1966) . The UTI's bacteria with concentration of 10 6 cfu/mL in NA medium was poured to Petri disc. Then, twelve-day old actinomycetes were cut with sterile straw of 6 mm at diameter and placed on NA medium containing the test bacteria. They were incubated at 37 o C for 24 hours. After that, inhibition area was measured and the inhibition index was calculated using the Inhibition Index (II) formula below. Isolates with the largest inhibition zone were selected to be cultured in liquid ISP 4 (inorganic saltsstarch) medium and shaken on the shaker incubator at 120 x g speed, 27-30 o C for 12 days. The supernatant and pellet were divided using centrifuge (HERMILE Labortechnik GmbH type Z326 K) at speed of 4000 x g, 4 o C for 15 minutes. Supernatant was dropped at paper disc that was placed on NA medium with 10 6 cfu/mL concentration of UTI's bacteria. It was incubated at 37 o C for 24 hours. Then, the inhibition area was measured to confirm the antibacterial activity from bioactive compounds inside (Sharma et al. 2011 ).
Inhibition index (II) = Diameter inhibition area (mm) -diameter colony (mm)
Diameter colony (mm)
Characterization of bioactive compounds as antibacterial
For the characterization of antibacterial compounds from potential actinomycetes, the supernatant was extracted using a solvent. The supernatant was mixed with ethyl acetate with a ratio of 1:1 v/v. The solution was shaken gently for 30 minutes until it exhibited the liquid phase on top of the solution. Then, the top phase was evaporated at 50 o C for 30 minutes using a rotary evaporator. Afterward, the crude extract was dissolved in DMSO 100% until the solution reached 0.01 g/mL concentration. The solution was tested at paper disc placed on NA medium with 10 6 cfu/mL concentration test bacteria, then incubated at 37 o C for 24 hours. A commercial antibiotic was used as positive control (ciprofloxacin 500 mg) in 5 μg/mL concentration. After that, the crude extract was characterized using GC-MS in Center Laboratory of Forensic, Mabes Polri, South Jakarta, Indonesia. The equipment was set by oven started with temperature of 80 o C until 350 o C and the injector started at 300 o C with solvent separation 10:1. Then, the 1 μL sample volume was injected. Helium was used as a gas carrier at 0.9 mL/minutes speed. The operated column type was Agilent 19091S-433 (length 30 m, diameter 0.25 mm, thickness 0.25 μm) with 30 minute time scanning. The result of chromatogram was then matched with Willey (W10N14) library database to identify bioactive compounds inside.
Molecular identification of potential actinomycetes based on 16S rRNA gene and construction of phylogenetic tree
DNA of 12 day old potential actinomycetes was extracted using PrestoTM Mini gDNA Bacteria Kit. The total DNA concentration was quantified by using nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, USA). Afterward, DNA was amplified using PCR TIThermocycler (Biometra, Goettingen, Germany) to confirm bacterial identity. Amplification was carried out using primer 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 16Sact1114R
(5'-GAGTTGACCCCGGCRGT-3') (Martina et al. 2008 o C for 1 minute. After that, the 16S rRNA gene was sequenced by commercial company (First base). The sequencing result was trimmed using Seqtrace 0.90. Then, nucleotide base was aligned using Basic Local Alignment Sequence for nucleotide (BLAST-N). The phylogeny tree was constructed using Mega 6.0 by maximum likelihood method with bootstrap replication 1000x (Tamura et al. 2013) .
RESULTS AND DISCUSSION
Screening of actinomycetes producing antibacterial compounds
Twenty-one actinomycetes, which were screened, showed 20 isolates inhibited at least one UTI's bacteria. There was variance at inhibition zone produced by actinomycetes. The spectrum of inhibition was narrow through the wide spectrum (Table 1) . Isolate code ARJ 16, 24, and 36 exhibited wide spectrum and the largest inhibition zone than others.
Crude extract inhibition of potential actinomycetes and its bioactive compounds
The amount of extraction product varied at each isolate code. The crude extracts produced by ARJ 16, ARJ 24, and ARJ 36 were about 0.133 g, 0.287 g, 0.025 g, respectively. Supernatant and crude extract of selected actinomycetes inhibited all UTI's bacteria (Table 2) . On the other hand, there were several bioactive compounds in ethyl acetate crude extract in various abundance. The highest abundance of bioactive compounds from ARJ 16, 24, and 36 were Propane, 1,2-dichloro, n-Hexadecanoic acid, and Carbonochloridic acid, 2-chloroethyl ester, respectively (Table 3 ).
Molecular identification of potential actinomycetes based on 16S rRNA gene
The 16S rRNA genes were successfully amplified by primer 27F and 16Sact1114R (~1100 bp). The result from NCBI BLAST showed that ARJ 16 and ARJ 24 were 99% similar with Streptomyces sp. strain TES 17, while ARJ 36 was 98% similar with Streptomyces tendae strain CMU RKDM 16 (Table 4) . Based on the BLAST-N result, the phylogeny tree was constructed. It showed that ARJ 16 and 24 were closely related to Streptomyces sp. with bootstrap value 99, while ARJ 36 was closely related to Streptomyces tendae with bootstrap value 90 (Figure 1) .
Each sequence of 16S rRNA gene potential actinomycetes was deposited to GenBank. Then, it obtained the accession number for ARJ 16, 24, and 36 were MK024250, MK024254, and MH633728, respectively. Streptomyces tendae strain CMU-RKDM 16 100% 0.0 98% LC310913 Figure 1 . Phylogenetic tree of actinomycetes producing UTI's antibacterial using maximum likelihood method with bootstrap 1000 replicates. Bacillus sp. was used as out-group. Bar 0.02 indicated nucleotide substitution per site
Discussion
We have screened 21 actinomycetes against UTI's bacteria. They showed that 20 (95%) isolates inhibited at least one of UTI's bacteria group. Previous research reported, that actinomycetes from arid zone of Badia region, Jordan showed 30% inhibited the test bacteria (Saadoun and Gharaibeh 2003) . Other cases showed that fifty isolates from farming soils in Turkey revealed antibacterial activity of 17 tested (39%) (Oskay et al. 2004) . Then, all isolates from soil at Cukuva University, Turkey was also reported to be inhibited test bacteria in medium glycerol-yeast agar, at least one test bacteria (Sarigullu et al. 2013) . It gave evidence that actinomycetes were able to produce many antibacterial compounds.
In this study, isolate code of ARJ 16, 24, and 36 were mentioned as potential actinomycetes because they showed greatest inhibition zone in terms of cell activity. That becomes a reason to check the supernatant and crude extract inhibition of each potential isolates for the next test. The supernatant and crude extract inhibited UTI's bacteria. This fact indicated that antibacterial compounds were excreted to liquid medium by the cell. However, the supernatant ability of each isolate was different. Several supernatants showed smaller inhibition zone than cell activity. This fact is due to the character of antibacterial compounds and sensitivity level of test bacteria. Previous research has shown that bioactive compounds are more stable in immobilized cell than free cell (Dhananjeyan et al. 2010) . The similar condition happened to crude extract. It could inhibit UTI's bacteria that indicated antibacterial compound was successfully extracted by ethyl acetate. This case can be explained by various bioactive compounds revealed by GC-MS (Table 3) .
Based on the above data, ARJ 16 and 24 crude extract inhibition index to all E. coli strain showed smaller than ciprofloxacin. The same thing happened to ARJ 36 crude extract to E. coli strain 2 and 3. This fact is due to the variance of bioactive compounds included in ARJ 16, 24, and 36 crude extract that gave another therapeutic activity besides antibacterial, such as antioxidant, antiinflammation, antifungal, or antineuro-degenerative (Table 3) . Meanwhile, ciprofloxacin was antibiotic with pure antibacterial compound. So, in this case, ciprofloxacin pointed out the greater action than crude extract. However, the data indicated that all crude extract inhibition index was the same with ciprofloxacin to A. calcoaceticus. It was suspected that bacteria sensitivity by antibiotic was decreased. Other things were exactly different by all of crude extracts against C. braakii and K. pneumoniae. They were not inhibited by ciprofloxacin and showed large inhibition index by crude extract. It showed that they had ciprofloxacin resistance. In addition, Reis et al. (2016) also reported that K. pneumoniae from UTI's patient showed resistant to ciprofloxacin and many other antibiotics.
Each bioactive compounds had different abundance and retention time. The ARJ 16 crude extract had Propane, 1,2-dichloro as bioactive compound with highest abundance included. Thirty percent of ARJ 16 crude extract was reported as antibacterial. Benzenediazonium, 4-hydroxy-, hydroxide, inner salt was one of bioactive compound in ARJ 16 crude extract that reported as antibacterial against E.coli, Pseudomonas aeruginosa, and Salmonella typhi (Johnson et al. 2013) . Then, the ARJ 24 ethyl acetate crude extract revealed 30% antibacterial activity. Interestingly, in this extract, there was procucumenol as anti-inflammation (Table 3) . It could be a benefit in the future because, in the same extract, we got combination between antibacterial and anti-inflammation those their work always complemented each other. One of antibacterial compounds which becomes the property compound of ARJ 16, 24, and 36 crude extract was hexadecanoic acid. It was fatty acids group and reported to inhibit E.coli and Salmonella sp. growth (Pu et al. 2010) . The ARJ 36 crude extract showed that most of them (50%) are antibacterial compounds. Carbonochloridic acid, 2-chloroethyl ester was highest abundance included. Several antibacterial compounds in ARJ 36 was 1,3-Cyclopentanedione and 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy-6-methyl. That was alicyclic hydrocarbon and flavonoid, respectively which inhibit K. pneumoniae, E. coli, and P. aeruginosa (Hamza et al. 2015) . Acetic acid, phenyl was carboxylic acid group that was reported as ear dunk human antibacterial (Thorp et al. 1998) .
Three potential actinomycetes were identified as 16S rRNA genes. Based on BLAST result, they were similar to the genus Streptomyces. This genus is known as a huge antibacterial producer. As previous study reported, Streptomyces sp. collected from soil sample of agriculture showed antibacterial activity against Staphylococcus epidermidis (Kumar et al. 2014) . The same species from hills soil produced antibacterial compounds for Enterobacter aerogenes (Balachandran et al. 2015) . In addition, the genus Streptomyces also inhibit methicillinresistant Staphylococcus aureus (MRSA), vancomycinresistant Staphylococcus aureus (VRSA), vancomycinresistant Enterococcus (VRE), and extended-spectrum lactamase (ESBL) producing bacteria (Sharma et al. 2011) . In this research, although ARJ 16 and 24 were the same species, we suspected that they were different strain. It is caused by the different bioactive compound which they produced. It could be proposed that Streptomyces sp strain ARJ 16, Streptomyces sp. strain ARJ 24, and Streptomyces tendae could inhibit UTI's bacteria growth by producing many bioactive compounds, especially antibacterial compounds. This study could be a reference for the development of UTI's antibacterial agents in the future. Perhaps, we could improve the antibacterial property by enhancing the culture condition, extraction method, or molecular method.
